Arbutus Biopharma
ABUS
ABUS
153 hedge funds and large institutions have $340M invested in Arbutus Biopharma in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1.37% more ownership
Funds ownership: 53.55% → 54.92% (+1.4%)
2% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $2.35M
13% less capital invested
Capital invested by funds: $389M → $340M (-$48.9M)
Holders
153
Holding in Top 10
5
Calls
$2.41M
Puts
$2.35M
Top Buyers
| 1 | +$2.87M | |
| 2 | +$2.64M | |
| 3 | +$2.35M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.03M |
| 5 |
WCM
Whitefort Capital Management
New York
|
+$1.22M |
Top Sellers
| 1 | -$5.71M | |
| 2 | -$4.09M | |
| 3 | -$1.75M | |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$1.47M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.08M |